½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > ÆäËû¿¹Ìå > VHL¿¹Ô­£¨ÖØ×éµ°°×£©

²úÆ·ÖÐÐÄ

×îвúÆ·

  • VHL¿¹Ô­£¨ÖØ×éµ°°×£©

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW20111
    • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º1mg/100ug
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ£º VHL¿¹Ô­£¨ÖØ×éµ°°×£©

Ó¢ÎÄÃû³Æ£º VHL Antigen (Recombinant Protein)

±ð     Ãû£º  RCA1; VHL1; pVHL; HRCA1

´¢     ´æ£º  Àä¶³£¨-20¡æ£©

Ïà¹ØÀà±ð£º ¿¹Ô­

¸Å     Êö

Full length fusion protein

¼¼Êõ¹æ¸ñ

Full name:

von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase

Synonyms:

RCA1; VHL1; pVHL; HRCA1

Swissprot:

P40337

Gene Accession:

BC058831

Purity:

>85%, as determined by Coomassie blue stained SDS-PAGE

Expression system:

Escherichia coli

Tags:

His tag C-Terminus, GST tag N-Terminus

Background:

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.



¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿